Cobitolimod
InDex Pharmaceuticals
['dance', 'inflammatory,bowel']
 announced attendance at the #ecco2023 congress, the largest forum for specialists in inflammatory bowel disease, to progress their lead drug candidate cobitolimod and the phase iii program conclude.
link: 
For Investors: News, Research and Events on Scandinavian equities. DISCLAIMER: https://t.co/P8pmew5Tb4